COMMUNIQUÉS West-GlobeNewswire

Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland
01/06/2026
REYKJAVIK, ICELAND (June 1, 2026) — Alvotech (Nasdaq: ALVO) and Islandsbanki have renewed and amended their existing market making agreement. According to the agreement, Islandsbanki places bids and offers for ALVO [...]
Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases
01/06/2026
HELSINKI, June 01, 2026 (GLOBE NEWSWIRE) -- Aplagon , a clinical-stage biotech developing first-in-class therapies for thromboinflammatory diseases, today announced the comprehensive publication of an invited review [...]
ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026
01/06/2026
Analysis from the Phase 3 COMPETE trial suggests population-based modeling may enable accurate individualized dosimetry with substantially fewer imaging requirements Los Angeles, California, June 1, 2026 — ITM Isotope [...]
Curium Announces a Strategic Investment of Over €32 million in Saclay, France
01/06/2026
Curium’s strategic investment of over €32 million will establish a European production line for 177 Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer This investment [...]
Intravacc and Primrose Bio Renew Partnership to Enhance Conjugate Vaccine Development
01/06/2026
The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development [...]
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
01/06/2026
New Cosentyx ® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase III extension study [...]
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
01/06/2026
Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard of care versus [...]
IBA lance Cyclone® iKure, un cyclotron conçu pour la production d’Astate-211 à l’échelle industrielle
01/06/2026
Louvain ‑ la ‑ Neuve, Belgique, le 1 er juin 2026 — IBA (Ion Beam Applications S.A., EURONEXT) , leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de production de [...]
New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
01/06/2026
The findings demonstrate that aprocitentan may help reduce the risk of kidney disease progression, cardiovascular events, and mortality in patients with resistant hypertension. Allschwil, Switzerland – June 01, 2026 [...]
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology
01/06/2026
High-dose cohort confirms the favorable safety profile and the dose-dependent immune response against Clostridioides difficile bacteria and spores Allschwil, Switzerland – June 1, 2026 Idorsia Ltd (SIX: IDIA) today [...]
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
01/06/2026
Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity Late [...]
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
01/06/2026
Multiple confirmed partial and minor responses observed in patients with SGC Continuing very good safety profile, with removal of the lifetime maximum doxorubicin limit based on highly favorable cardiac safety LONDON [...]
IBA launches Cyclone® iKure, a cyclotron designed for industrial scale Astatine-211 production
01/06/2026
Louvain-la-Neuve, Belgium – 01 June 2026 – IBA (Ion Beam Applications S.A., EURONEXT) , the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today [...]
SEIMC Launches Precision Gallbladder-Preserving Treatment to Safeguard Biliary Health
01/06/2026
SHANGHAI, May 31, 2026 (GLOBE NEWSWIRE) -- On March 14, 2026, Shanghai East International Medical Center (SEIMC) achieved a major milestone in global minimally invasive biliary treatment by successfully completing its [...]
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
01/06/2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the [...]
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
01/06/2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the [...]
BriaCell Therapeutics Announces Pricing of Offering
01/06/2026
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
01/06/2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the [...]
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
31/05/2026
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment [...]

Pages